Calfactant

Drug Overview

In the highly specialized field of Pulmonology, critical care interventions often require immediate, life-saving therapies that support the most fundamental mechanics of breathing. Calfactant represents one of the most vital interventions for patients suffering from acute respiratory failure, particularly in the fragile neonatal population. Unlike a daily maintenance Inhaled Corticosteroid (ICS) or a standard Bronchodilator used to manage chronic airway conditions, this medication is a foundational rescue therapy designed to establish normal lung function at the very beginning of life.

Operating within the Pulmonary Surfactant drug class, this medication is an exogenous (externally administered) biological substance that directly replaces the natural lung compounds missing in premature infants. It is a critical tool for pulmonologists and neonatologists to prevent the devastating consequences of lung collapse and severe respiratory distress.

• Generic Name: Calfactant
• US Brand Names: Infasurf
• Drug Category: Pulmonology
• Drug Class: Pulmonary Surfactant
• Route of Administration: Intratracheal suspension (instilled directly into the lungs via an endotracheal tube)
• FDA Approval Status: Fully FDA-approved for the prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants.

What Is It and How Does It Work? (Mechanism of Action)

Calfactant is a sterile pulmonary surfactant derived from calf lungs, containing phospholipids (mainly DPPC) and surfactant proteins SP-B and SP-C. In alveoli, surface tension from the fluid lining normally promotes collapse, especially during exhalation. Premature infants lack sufficient endogenous surfactant due to immature Type II pneumocytes, leading to atelectasis and respiratory failure. When administered intratracheally, calfactant rapidly spreads across alveolar surfaces, reducing surface tension and stabilizing alveoli. This improves lung compliance, supports ventilation, enhances gas exchange, and reduces the need for high-pressure mechanical ventilation, thereby lowering the risk of ventilator-induced lung injury.

FDA-Approved Clinical Indications

• Primary Indication: The prevention (prophylaxis) of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS, and the rescue treatment of premature infants who have already developed clinical RDS.

Other Approved & Off-Label Uses. While primarily a neonatal intervention, the principles of surfactant replacement are deeply intertwined with broader pulmonary disease states characterized by severe alveolar damage and surfactant dysfunction.

• Primary Pulmonology Indications:
  • Meconium Aspiration Syndrome (MAS) (Off-Label): Used to restore alveolar stability when an infant inhales meconium before or during birth, which chemically deactivates natural lung surfactant and triggers severe inflammation.
  • Acute Respiratory Distress Syndrome (ARDS) (Off-Label): Utilized in specialized pediatric and adult critical care pulmonology for severe ARDS resulting from systemic infections, pneumonia, or drowning, where native surfactant has been destroyed by intense alveolar inflammation.
  • Severe Viral Bronchiolitis (Off-Label): Occasionally utilized in extreme pediatric cases of RSV or other viral infections to improve ventilation, slow the decline of lung function, and reduce the need for prolonged extracorporeal membrane oxygenation (ECMO).

Dosage and Administration Protocols

Because this is an intratracheal suspension, administration is strictly confined to intensive care settings by practitioners highly trained in advanced airway management.

Dose Adjustments and Administration Instructions:

• Pediatric Weight-Based Dosing: The standard dose is strictly calculated at 3 mL/kg based on the infant’s birth weight.
• Administration Technique: The dose is divided into two or four smaller aliquots (portions). Each aliquot is instilled directly into the endotracheal tube while the infant is briefly disconnected from the ventilator, or via a specialized dual-lumen catheter. The infant’s position is changed between aliquots to ensure the drug distributes evenly throughout all lung lobes.
• Organ Function Impact: No dose adjustments are required for hepatic or renal impairment, as the drug acts topically within the lung tissue and is recycled by alveolar cells rather than cleared systemically.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical study data (2020-2026) continues to validate exogenous surfactant as a cornerstone of critical care pulmonology. While adult pulmonology often measures success via improvements in Forced Expiratory Volume (FEV1) or 6-minute walk distance (6MWD), neonatal and critical care efficacy is measured through oxygenation indices, ventilator weaning, and survival rates.

Extensive clinical trials demonstrate that the prophylactic administration of calfactant in extreme premature cohorts significantly reduces the incidence of pneumothorax (lung rupture) by 30% to 40% compared to non-surfactant control groups. Furthermore, in rescue scenarios, calfactant rapidly decreases the required Fraction of Inspired Oxygen (FiO2) and lowers mean airway pressures on the mechanical ventilator within hours of administration. Recent observational data highlights that early administration effectively improves the trajectory of lung healing, substantially reducing the long-term risk of developing Bronchopulmonary Dysplasia (BPD)—a chronic obstructive airway disease that plagues premature infants later in life.

Safety Profile and Side Effects

Black Box Warning: There is currently no Black Box Warning associated with calfactant.

Common Side Effects (>10%):

• Transient bradycardia (temporary drop in heart rate during instillation)
• Transient oxygen desaturation (drop in blood oxygen levels during dosing)
• Endotracheal tube reflux (the drug backing up into the breathing tube)
• Temporary airway obstruction due to the liquid volume of the medication

Serious Adverse Events:

• Pulmonary Hemorrhage: Bleeding into the lungs, which occurs in rare cases but requires immediate intensive care management.
• Apnea: Cessation of spontaneous breathing, necessitating increased mechanical ventilator support.
• Barotrauma: If ventilator settings are not rapidly turned down as the surfactant takes effect, the suddenly compliant lungs can over-inflate and rupture (pneumothorax).

Management Strategies: During administration, continuous heart rate monitoring and Pulse Oximetry (SpO2) are mandatory. If bradycardia or severe oxygen desaturation occurs, the instillation must be paused, and the patient must be actively ventilated with higher oxygen concentrations until stabilized. Healthcare providers must remain hyper-vigilant post-administration; as lung elasticity rapidly improves, ventilator pressures must be aggressively “stepped-down” to prevent lung rupture.

Research Areas

Current pulmonology research is heavily focused on optimizing how we protect the delicate respiratory epithelium. Direct clinical connections are being investigated regarding calfactant’s role in mitigating long-term airway remodeling. By preventing the initial intense mechanical trauma of ventilating a non-compliant lung, researchers are studying how surfactant therapy preserves the normal structural development of the lung matrix and promotes natural mucociliary clearance.

A major focus of clinical trials from 2020 to 2026 involves advancements in Novel Delivery Systems. Because traditional administration requires invasive intubation, researchers are pioneering Less Invasive Surfactant Administration (LISA) and aerosolized/nebulized surfactant delivery. These methods aim to deliver the medication via CPAP directly to the lungs without the trauma of an endotracheal tube. Furthermore, in the realm of severe disease and precision medicine, scientists are exploring how exogenous surfactants might act as carrier molecules for Targeted Therapy or Biologic agents, delivering powerful anti-inflammatory or gene-editing treatments directly to the alveolar surfaces of patients suffering from severe, end-stage fibrotic lung diseases or acute respiratory distress syndrome.

Disclaimer:  The research discussed in the “Research Areas” section reflects emerging and experimental concepts in neonatal and pulmonary medicine. These studies are still in early or exploratory stages and may include theoretical or preclinical findings. They are not yet validated for routine clinical use and are not applicable to current standard medical practice or professional clinical decision-making. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Baseline Chest X-ray is vital to confirm the classic “ground-glass” appearance characteristic of RDS and to verify proper endotracheal tube placement. Continuous Pulse Oximetry (SpO2) and arterial blood gas (ABG) analyses are required to establish the severity of hypoxic respiratory failure.
• Organ Function: Continuous baseline heart rate, blood pressure, and perfusion monitoring are absolute prerequisites before initiating therapy.
• Specialized Testing: While tools like Fractional Exhaled Nitric Oxide (FeNO) or sputum eosinophil counts are standard in outpatient asthma, in the neonatal ICU, continuous monitoring of pulmonary mechanics (lung compliance, tidal volume) via the mechanical ventilator serves as the primary specialized testing.
• Screening: Immediate verification of gestational age, birth weight, and the mother’s prenatal history (including maternal steroid administration) guides the urgency and dosage of therapy.

Monitoring and Precautions

• Vigilance: Continuous monitoring for rapid changes in lung mechanics is the highest priority. Practitioners must perform immediate “Step-down” therapy on the mechanical ventilator. As the calfactant takes effect, the lungs become softer and easier to inflate; leaving the ventilator at high pressures will cause immediate lung injury.
• Lifestyle/Handling: For the clinical team, handling the medication requires specific protocols. The vial must be stored in the refrigerator but warmed to room temperature for at least 20 minutes before use.
• “Do’s and Don’ts” list:
  • Do: visually inspect the vial; the suspension should be an off-white, opaque liquid.
  • Do gently swirl the vial to uniformly suspend the active ingredients prior to drawing up the dose.
  • Do: ensure the infant is properly suctioned and the endotracheal tube is clear before administration.
  • Don’t shake the vial vigorously, as this will cause the biological proteins to foam and degrade.
  • Don’t dilute the medication with saline or any other fluid.
  • Don’t unnecessarily suction the infant’s airway for at least 1 to 2 hours after administration to allow the drug to fully coat the alveoli.

Legal Disclaimer

This guide is intended exclusively for educational and informational purposes and does not constitute professional medical advice, diagnosis, or treatment. The clinical scenarios discussed, including critical care interventions, require management by specialized pulmonologists, neonatologists, and intensive care practitioners. Always seek the advice of a qualified healthcare provider regarding any questions related to a medical condition or treatment protocol. Do not disregard professional medical advice or delay seeking it due to the information contained within this document.